Result of GM, Issue of Equity, Warrants and TVR
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
Director/PDMR Shareholding
ValiRx plc (the "Company") (AIM: VAL), announces that, further to the Conditional Fundraising & Notice of General Meeting announcements on 9 December 2024 and 10 December 2024, at its General Meeting held earlier today, all resolutions were duly passed. Details of the votes received in respect of the resolutions will be available shortly on the Company's website.
In aggregate the Company has issued 241,999,999 New Ordinary Shares and 241,999,999 Fundraise Warrants over new ordinary shares.
The Fundraise Warrants are exercisable for a period of three years from Admission and are exercisable at a price of 1.3 pence per new ordinary share.
Director/PDMR Shareholdings
Following completion of the Fundraising, the shareholdings of the Directors and persons closely associated with them who have participated in the Fundraising are set out in the table below:
| Name | Number of existing Ordinary Shares | Percentage of existing issued share capital | Number of New Ordinary Shares | Number of Ordinary Shares on Admission | Percentage of enlarged share capital on Admission | Number of Fundraise Warrants |
|---|---|---|---|---|---|---|
| Mark Eccleston | 1,976,957 | 1.49% | 20,769,230 1 | 22,746,187 | 6.08% | 20,769,230 |
| Adrian de Courcey | 871,036 | 0.66% | 1,538,461 | 2,409,497 | 0.64% | 1,538,461 |
| Cathy Tralau-Stewart | 66,666 | 0.05% | 769,231 | 835,897 | 0.22% | 769,231 |
| Gerry Desler | 195,334 | 0.15% | 769,231 | 964,565 | 0.26% | 769,231 |
| Martin Gouldstone | 0 | 0.00% | 769,231 | 769,231 | 0.21% | 769,231 |
| Total | 3,109,993 | 2.35% | 24,615,384 | 27,725,377 | 7.41% | 24,615,384 |
1of which, 9,846,145 New Ordinary Shares have been subscribed for by Mark Eccleston directly, 5,538,470 New Ordinary Shares have been subscribed for by OncoLytika Ltd (a company in which Mr. Eccleston is interested) and 2,307,692 New Ordinary Shares have been subscribed for by Mark Eccleston's partner. In addition, Mr Eccleston subscribed for a further 3,076,923 New Ordinary Shares as part of the Broker Offer
Issue of Equity
The Placing Shares, the Subscription Shares and the Broker Offer Shares have been allotted, conditional upon Admission, and application has been made to the London Stock Exchange for, in aggregate, 241,999,999 Placing Shares, Subscription Shares and Broker Offer Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on or around 31 December 2024, with dealings in the Placing Shares, the Subscription Shares and the Broker Offer Shares commencing at the same time. The Placing Shares, the Subscription Shares and the Broker Offer Shares will rank pari passu with all other issued Shares.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 374,348,672 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in the Conditional Fundraising announcement dated 9 December 2024, unless otherwise defined in this announcement.
The Directors of the Company take responsibility for this announcement.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/vPn48e |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 (0) 2476 796496 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 7186 9000 |
| V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | a) Mark Eccleston b) OncoLytika Ltd c) Annette Williams d) Adrian De-Courcey e) Cathy Tralau-Stewart f) Gerry Desler g) Martin Gouldstone |
| 2 | Reason for notification | |
| a. | Position/Status | a) Director b) A company which Mark Eccleston has an interest c) PCA of Mark Eccleston d) Director e) Director f) Director g) Director |
| b. | Initial notification/ Amendment | Initial notification |
| a. | Name | ValiRx PLC |
| b. | LEI | 213800VQKB9SJCQDET40 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares ISIN: GB00BLH13C52 |
| b. | Nature of the transaction | Purchase of shares as part of the Fundraising |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| a) 0.65p b) 0.65p c) 0.65p d) 0.65p e) 0.65p f) 0.65p g) 0.65p | a) 12,923,068 b) 5,538,470 c) 2,307,692 d) 1,538,461 e) 769,231 f) 769,231 g) 769,231 | |
| d. | Aggregated information - Aggregated Volume - Price | N/A |
| f. | Place of the transaction | Outside a trading venue |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | a) Mark Eccleston b) OncoLytika Ltd c) Annette Williams d) Adrian De-Courcey e) Cathy Tralau-Stewart f) Gerry Desler g) Martin Gouldstone |
| 2 | Reason for notification | |
| a. | Position/Status | a) Director b) A company which Mark Eccleston has an interest c) PCA of Mark Eccleston d) Director e) Director f) Director g) Director |
| b. | Initial notification/ Amendment | Initial notification |
| a. | Name | ValiRx PLC |
| b. | LEI | 213800VQKB9SJCQDET40 |
| a. | Description of the financial instrument, type of instrument Identification Code | Warrants over Ordinary Shares with an exercise price of 1.3 pence per share and exercisable for a period of three years from Admission. ISIN: GB00BLH13C52 |
| b. | Nature of the transaction | Fundraise Warrants received as part of the Fundraising |
| c. | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| a) 1.3p b) 1.3p c) 1.3p d) 1.3p e) 1.3p f) 1.3p g) 1.3p | a) 12,923,068 b) 5,538,470 c) 2,307,692 d) 1,538,461 e) 769,231 f) 769,231 g) 769,231 | |
| d. | Aggregated information - Aggregated Volume - Price | N/A |
| f. | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.